The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...